News

06 April 2021
UNION therapeutics’ COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication
Read More
29 March 2021
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
Read More
22 February 2021
UNION’s nasal spray for COVID-19 enters a 1,500 high-risk patient study
Read More
09 February 2021
UNION Completes Over-subscribed 155m DKK Equity Capital Raise to Accelerate Clinical Programs
Read More
07 January 2021
UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis
Read More
28 October 2020
UNION therapeutics appoints Dr. Kim Kjoeller as Chief Executive Officer and further strengthens leadership by appointing Dr. Günter Ditzinger as Chief Technology Officer
Read More
21 October 2020
Danish biotech UNION therapeutics A/S adds program to prevent COVID-19 with intranasal delivery of niclosamide
Read More
25 August 2020
UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19
Read More
13 August 2020
UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.
Read More
22 July 2020
Spatial and Temporal Dynamics of SARS-CoV-2 in COVID-19 Patients - A Systematic Review and Meta-Analysis Published in EBioMedicine
Read More
21 July 2020
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
Read More
01 July 2020
The Journal of Investigative Dermatology Publish UNION therapeutics' Phase 2 Clinical Trial Results
Read More
01 July 2020
UNION receives approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19
Read More
02 April 2020
UNION therapeutics launches COVID-19 program in collaboration with Institut Pasteur Korea
Read More
01 November 2019
UNION initiates Phase 2b Dose-Ranging Study Evaluating ATx201 OINTMENT in Patients with Mild-to-Moderate Atopic Dermatitis
Read More
01 July 2019
UNION achieves study completion milestone in UNI836 collaboration with Ceva Santé Animale S.A.
Read More
07 February 2019
UNION therapeutics A/S Announces Global License Agreement with Ceva Santé Animale S.A.
Read More
19 December 2018
UNION therapeutics Announces Completion of Phase 2 studies with ATx201
Read More
29 October 2018
UNION therapeutics Announces Successful Phase 1 Study Completion with ATx201
Read More
09 October 2018
AntibioTx Announces Company Name Change to UNION therapeutics
Read More
01 July 2018
AntibioTx Expands Management Team with Dr. Umar Hayat
Read More
25 June 2018
AntibioTx Announces Positive Data Supporting the Safety of ATx201
Read More
02 April 2018
AntibioTx Strengthens Management Team with CFO and VP of Commercialization
Read More
01 November 2017
FDA Approves IND to Conduct Clinical Studies with ATx201 in USA
Read More
26 October 2017
AntibioTx Signs 150 M DKK Financing Agreement with the European Investment Bank
Read More
02 June 2017
AntibioTx to Present Phase I DECOLAD Results at the 26th EADV
Read More
22 May 2017
AntibioTx Announces New Board Members
Read More
05 April 2017
AntibioTx Announces Phase I Study Results for ATx201
Read More
24 March 2017
AntibioTx Announces Reward of Grant Funding to Conduct Clinical Biomarker Study with ATx201
Read More
15 March 2017
AntibioTx Signs Dr. Philippe Prokocimer as Chief Medical Officer and Establishes US Subsidiary
Read More
15 February 2017
AntibioTx Expands Management Team with new VP of Drug Regulatory Affairs
Read More
14 November 2016
AntibioTx Invited to Present at Berlin Antimicrobial Conference
Read More
19 September 2016
AntibioTx Concludes 28-day Repeat Dosing in Göttingen Minipigs with Positive Results
Read More
06 September 2016
AntibioTx Invited to Publish ATx201 Results at the ‘2nd Inflammatory Skin Disease Summit’ (New York)
Read More
19 August 2016
AntibioTx Enters Collaboration with Dr. Keith Bostian to Establish Medicinal Chemistry Program
Read More
07 August 2016
In vivo Efficacy Studies of ATx201 Compares Favorably with Marketed Products
Read More
16 May 2016
Horizon2020 Grant Awarded to Consortium (Train2Target) Comprising AntibioTx
Read More
07 April 2016
Collaboration Initiated with Prof. Mylonakis (Brown University) to Further Elucidate MoA and New Indication Opportunities
Read More
22 March 2016
In vivo Study in Minipigs Confirmed Systemic Safety and No Genotoxicity of ATx201
Read More
26 October 2015
AntibioTx Rewarded Grant Funding to Conduct Phase 1 and Phase 2 Studies in Atopic Dermatitis Patients
Read More